BackSingular Genomics Systems Overview

Singular Genomics Systems Total Liabilities

Singular Genomics Systems's total liabilities is $63M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$63.30M
25.96% YoYΔ $-22.19M vs prior year quarter

Peer trimmed avg / median

Loading

Singular Genomics Systems Total Liabilities History

Loading

Singular Genomics Systems vs. peers: Total Liabilities Comparison

Loading

Singular Genomics Systems Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Singular Genomics Systems (OMIC) FAQ

Singular Genomics Systems's total liabilities stands at $63M as of September 2024. That compares with $85M in the prior-year period — down 26.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Singular Genomics Systems reported $63M in total liabilities versus $85M a year earlier — a 26.0% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $85M in the prior-year period — down 26.0% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Singular Genomics Systems's total liabilities evolved across reporting periods, while the comparison chart places OMIC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total liabilities is commonly used to spot outliers. Singular Genomics Systems's reading of $63M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.